NOW AVAILABLE: For the European PCSK9 Inhibitors Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q3, 2016.

The volume of promotional pieces decreased during Q3 compared to the one generated in the previous quarter. Repatha became the promotional leader during this quarter by capturing 56% of promotional volume in the European PCSK9 inhibitors market. Praluent and Repatha emphasized their efforts through clinical studies to support efficacy, safety, and the role of PCKS9 inhibitors in the treatment of CV risk patients. Additional insights into marketing strategies and channel utilization are available in the full Q3 report.

Ex-US-2016-Q3-PSCK9-inhibit

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Primary Care Markets and Specialty Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com